Peptide Vendors Shut Down or Warned in 2025 to 2026: The Dated Record (September 2026)

Between January and September 2026 the research-peptide market lost its largest single storefront, its most prominent GLP-class specialist and at least two other long-running vendors, while the FDA issued three batches of warning letters to online peptide sellers and a federal court sentenced the owner of a fourth vendor to nearly six years in prison. This page is the Bureau's dated record of who closed, who was warned, and what the vendor or the regulator actually said, current to the first week of September 2026.

Ground rules. Every entry below is sourced either to the vendor's own notice or to a named public document (an FDA warning letter, a Department of Justice release, a USITC record). Where the Bureau could only find trade blogs repeating one another, the vendor is not listed. That means some names you may have seen elsewhere are absent; the last section explains which ones and why.

The dated record: closures and enforcement, 2025 to September 2026

A warning letter is not a closure. Each of the August recipients was given fifteen business days to respond, which for a letter dated 24 August runs to roughly 8 September 2026, and the FDA's stated next step for non-response is "seizure, and injunction" or other regulatory action. The Bureau has not checked whether each site is still trading and does not assert that any of them has closed.

Peptide Sciences: the one that changed the market

Peptide Sciences was, by most accounts, the highest-volume research-peptide storefront in the US. On 6 March 2026, at around 2:00 PM Eastern according to PeptideLaws.com, the site replaced its catalogue with a short notice. The version live in September 2026 reads: "After careful consideration, Peptide Sciences has decided to voluntarily shut down operations and discontinue the sale of its research products." It goes on to say the company retains its trademarks and "will continue to protect and enforce those rights", and that "any website, platform, entity, or individual claiming affiliation with Peptide Sciences, representing themselves as a successor to Peptide Sciences, or claiming to sell our products is unauthorized, fraudulent, and has no affiliation with our company." A reporting address, [email protected], is given for fraud.

What the notice does not say is why, or what happens to money already paid. PeptideLaws.com found no public FDA warning letter to Peptide Sciences and notes the company characterised the closure as voluntary; the Bureau's own search of the FDA warning-letter database in September 2026 found none either. The same source reports the notice gave "no timeline for potential return" and no refund process. The Bureau's fuller account is on the Peptide Sciences shutdown page.

Two practical consequences followed. First, a wave of look-alike domains and "successor" claims, which the vendor's own notice addresses. Second, a migration of buyers to vendors that had been second-tier, several of which then appeared in the FDA's August letters. If you are evaluating a vendor that markets itself as where Peptide Sciences customers went, the fake vendor checklist is the place to start.

Strate Labs: an orderly close with a paper trail

Strate Labs' notice, live on stratelabs.com when the Bureau fetched it, is the clearest of the year: "StrateLabs has permanently closed." It continues: "If you have a pending order, it will ship as scheduled. If for any reason we cannot fulfill an order you've placed, you will receive a full refund automatically, no action needed on your part." The company says it "removed all order history for safety reasons", set 1 August 2026 as the date the site would go offline, and gave [email protected] for questions. The stated reason is that the regulatory landscape "has shifted in ways that make it impossible" to continue at the company's standards.

Strate Labs also had a longer history with regulators than most. Amino Axiom's status page records that it was named among the respondents in Eli Lilly's tirzepatide complaint to the US International Trade Commission, filed 19 October 2023, with a default finding in May 2024 and a cease-and-desist order in early 2025. The vendor did not link the ITC matter to its closure. The Bureau's vendor page is at Strate Labs review.

Paradigm Peptides: the criminal case

This is the one entry on the list that ended in prison rather than a notice. On 30 July 2026 the US Attorney's Office for the Northern District of Indiana announced that Matthew J. Kawa, 48, of Grant Park, Illinois, had been sentenced to 70 months and Jennifer L. Stechkober, 32, of Michigan City, Indiana, to 16 months, each followed by a year of supervised release. Both had pleaded guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead; Kawa also pleaded to illegally importing merchandise. The court ordered $78,317.52 in restitution and a $5 million money judgment against Kawa.

The conduct described by prosecutors ran from 2019 to 2024 and reached more than 54,000 customers. The company sold peptides, SARMs, HCG and other compounds, claimed FDA licensing, US manufacturing and quality testing, and in fact imported untested product from China and India; many SARM products were mislabelled testosterone. The prosecutor's line was that the defendants "lied to the world at large saying their company was legitimate; their products were safe, pure, tested, and manufactured in the United States." For anyone who has ever wondered whether a vendor's COA can simply be forged, this case is the documented answer, and the peptide testing guide explains what an independent retest looks like.

The FDA warning letters: three batches, one legal theory

The FDA's 2026 letters to peptide vendors follow a template. Each names the products the agency found on the vendor's site, states that they are unapproved new drugs under sections 301(d) and 505(a) of the Federal Food, Drug and Cosmetic Act, and then addresses the research-only disclaimer directly. The Peptide Partners letter puts it this way: "Despite statements on your product labeling marketing your products 'for research use only' and 'not for human or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use." The Gram Peptides, Wholesale Peptide, Peak Performance, NuScience and Tex Peptides letters use the same construction almost word for word.

The evidence the FDA cites is marketing: describing a product's role in "the management of type 2 diabetes, obesity, and metabolic disorders" (Tex Peptides), selling bacteriostatic water alongside the vial, or bundling a reconstitution kit. Every letter adds that injectable products "bypass some of the body's key defenses against toxins". The March batch was almost entirely GLP-class compounds sold under coded names (GLP-1 S, GLP-2 T, GLP-3 R); the August batch broadened to SS-31, PT-141, tesamorelin and a tesamorelin/ipamorelin blend, plus in Wholesale Peptide's case gonadorelin and Prostamax.

The 3 March letters to thirty telehealth companies are a different action and are listed for completeness: they concerned marketing of compounded GLP-1 products, not research vials, and the FDA named no companies in its announcement. Commissioner Marty Makary's line was: "It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies."

What usually happens to open orders

The 2026 closures split into two patterns. Strate Labs published an explicit commitment: pending orders ship or are refunded automatically, with a contact address and a fixed date for the site to go dark. Science.bio and Peptide Sciences published a closure sentence and a warning about impostors, with no refund process on the page. If you had an open order with either of the latter, the Bureau has no vendor statement to point you to.

What researchers can do in that situation is limited but not nothing. A card payment can be disputed with the issuer within the network's time limit, usually 60 to 120 days from the charge, on the basis of goods not received. A crypto or wire payment cannot. That difference is the single strongest argument for paying vendors by card even where a crypto discount is offered. Keep the order confirmation, any tracking number and a screenshot of the closure notice; issuers ask for all three. If a vendor's notice says orders will ship, wait for the stated date before disputing, because a chargeback filed against a parcel that then arrives is a mess to unwind.

Warning-letter recipients are a separate case. Nothing in a warning letter stops a vendor trading while it responds, so an open order with one of the August recipients is not automatically at risk. The risk is that a vendor which does not respond, or cannot, closes without notice. If you have an order in flight with a vendor on the FDA list, the sensible move is to let it complete and not place another until the vendor has addressed the letter publicly.

The pattern behind the closures

Three forces show up repeatedly in the record. The first is the FDA's intended-use theory: a research-only label does not protect a vendor whose site describes what the compound does in a person. Every 2026 letter turns on this, and the March and August batches show the agency working through GLP-class sellers first and then widening to growth-hormone secretagogues and other injectables. The second is private enforcement by patent holders, most visibly Eli Lilly's ITC complaint over tirzepatide, which produced exclusion and cease-and-desist orders against named vendors including Strate Labs. The third is criminal exposure where a vendor lies about testing or origin, which is what separated Paradigm Peptides from the rest.

The vendors that closed voluntarily in 2026 had one thing in common: large GLP-class catalogues under coded names, which put them in the direct path of both the FDA and Lilly. Vendors with narrower catalogues, published batch COAs and marketing that stays inside laboratory language have so far been less exposed, though the August letters show the agency is now reading tesamorelin and PT-141 listings the same way it reads retatrutide. The how to buy peptides guide sets out what to check before an order; the storage guide covers what to do with a vial you already have. If you are reconstituting from a vial bought before a closure, the reconstitution calculator still does the arithmetic.

Vendors the Bureau currently scores

Disclosure. Links in this section may earn the Bureau a commission. None of the five vendors below appears in any FDA warning letter, USITC order or court record the Bureau found in September 2026; that is a statement about the public record on the date checked, not a guarantee. The scorecard weighs documentation, consistency, shipping and price, and the method is on the vendor scorecard page.

• Apollo Peptide Sciences: the Bureau's top-scored vendor. States free shipping on orders over $200 and shows a batch COA on the product page. Full review: Apollo Peptide Sciences review. Check price at Apollo Peptide Sciences
• Pantheon Peptides: batch lab results searchable by the number printed on the vial. Pantheon Peptides review.
• Amino Club: publishes "from" prices openly and states free shipping over $100. Amino Club review.
• Ascension Peptides: batch-specific third-party COAs on each product page, running sale pricing in September 2026. Ascension Peptides review.
• Limitless Life Peptides: the long-standing Florida vendor, prices behind a professional log-in. Limitless Life Peptides review.

Names deliberately left off the table. Arctic Peptides and Triggered Brand are widely described in forums as closed. The Bureau could not fetch a closure notice from either domain (arcticpeptides.com did not respond; triggeredbrand.com redirects to a different storefront that makes no mention of the brand) and found no primary document, so neither is listed. The same applies to Royal Research, PurchasePeptides, AffordablePeptides and several smaller names that appear only in trade round-ups. If a primary source appears, the table will be updated. Related vendor pages in this batch: Peptide Partners review, Direct Peptides review, Penguin Peptides review. Nothing here is medical advice; these are research compounds and the Bureau does not advise anyone on using them.

Frequently Asked Questions

Which peptide vendors shut down in 2026?

With a primary source: Science.bio announced permanent closure in late January 2026; Peptide Sciences posted a voluntary shutdown notice on 6 March 2026; Strate Labs posted a permanent closure notice on 1 July 2026 with its site scheduled to go offline on 1 August. Paradigm Peptides ended with its owner sentenced to 70 months on 30 July 2026. Amino Asylum went offline in June 2025 on trade reports only. Other names circulating in forums, including Arctic Peptides and Triggered Brand, could not be verified from a vendor notice or public record and are not listed.

Did Peptide Sciences get an FDA warning letter?

Not that anyone has found. The vendor described its 6 March 2026 closure as voluntary, and neither PeptideLaws.com nor the Bureau's own search of the FDA warning-letter database in September 2026 turned up a letter addressed to Peptide Sciences. The closure notice gives no reason, no refund process and no timeline for return, and warns that any site claiming to be a successor is fraudulent. Absence of a letter is not evidence of the reason for closing; it simply means the public record does not contain one.

What happens to my order if a peptide vendor closes?

It depends on what the vendor said. Strate Labs stated pending orders would ship or be refunded automatically. Peptide Sciences and Science.bio published no refund process. If you paid by card, a dispute for goods not received can be raised with the issuer, typically within 60 to 120 days of the charge; keep the confirmation, tracking and a screenshot of the notice. Crypto and wire payments cannot be reversed, which is the strongest argument for paying by card. Wait for any stated ship date before disputing.

Which vendors received FDA warning letters in 2026?

Three batches so far. On 31 March 2026: Gram Peptides, Lovega LLC (Pink Pony Peptides), Prime Sciences, PekCura Labs, Mile High Compounds and an eBay seller, mostly for GLP-class peptides under coded names. On 17 June 2026: Wholesale Peptide, for Prostamax and gonadorelin. On 24 August 2026, posted 1 September: Peptide Partners, Peak Performance Peptides, NuScience Peptides, TXP Innovations (Tex Peptides) and Royal Peptides, for GLP-class compounds plus SS-31, PT-141 and tesamorelin. Separately, 30 telehealth firms were warned on 3 March over compounded GLP-1 marketing.

Does a warning letter mean the vendor is shut down?

No. A warning letter gives the recipient fifteen business days to describe corrective action; the FDA's stated next step for non-response is seizure, injunction or other regulatory action. For the 24 August 2026 letters that deadline falls around 8 September. Vendors can and do keep trading while they respond. The Bureau has not checked whether each August recipient is still taking orders and does not claim any has closed. What a letter does establish is the FDA's position that research-only labelling does not protect products marketed with human-use claims.

Why are peptide vendors closing?

Three documented pressures. The FDA's intended-use theory, applied in every 2026 letter, holds that marketing language showing human use makes a research vial an unapproved drug. Patent holders, principally Eli Lilly through its USITC tirzepatide complaint, have obtained exclusion and cease-and-desist orders against named vendors including Strate Labs. And criminal prosecution follows where vendors lie about testing or origin, as in the Paradigm Peptides case. Vendors with large GLP-class catalogues sat in the path of all three. Strate Labs' own notice cited a regulatory landscape that had shifted.

Which vendors does the Bureau still score?

Five: Apollo Peptide Sciences, Pantheon Peptides, Amino Club, Ascension Peptides and Limitless Life Peptides. In the first week of September 2026 none appeared in an FDA warning letter, USITC order or court record the Bureau could find. That describes the public record on the date checked, not a guarantee about the future. The scorecard weighs documentation, consistency, shipping and price. Links to those vendors on this page are affiliate links and may earn the Bureau a commission, which funds its testing and does not change the price shown.

Research use only. The compounds discussed are sold as research chemicals and are not approved for human use. Nothing here is medical advice.